Incidence, clinical characteristics, and outcomes of nosocomial Enterococcus spp. bloodstream infections in a tertiary-care hospital in Beijing, China: a four-year retrospective study

Table 2 Comparison of the microbiological characteristics and treatment of patients with E. faecium and E. faecalis BSIs

	E. faecium (n = 167)	E. faecalis (n = 46)	p-value
Source of BSIs
Intra-abdominal	65 (39, 31–46)	19 (41, 27–56)	0.770
Unknown	53 (32, 25–39)	10 (22, 9–34)	0.188
Central venous catheter	30 (18, 12–24)	10 (22, 9–34)	0.562
Genitourinary	11 (7, 3–10)	3 (7, 0–14)	0.987
Pneumonia	4 (2, 0–5)	3 (7, 0–14)	0.165
Others	4 (2, 0–5)	1 (2, 0–7)	0.930
Type of BSIs
Polymicrobial	20 (12, 7–17)	1 (2, 0–7)	*0.048*
Antibiotic resistance^a
Ampicillin (137 vs 46)^b	118 (86, 80–92)	4 (9, 0–7)	*<0.001*
Gentamicin (93 vs 21) ^b	49 (53, 42–63)	7 (33, 11–55)	0.109
Tetracycline (105 vs 36) ^b	50 (48, 38–57)	22 (61, 44–78)	0.162
Erythromycin (105 vs 36) ^b	82 (78, 70–86)	20 (56, 39–73)	*0.009*
Ciprofloxacin (137 vs 46) ^b	118 (86, 80–92)	18 (39, 24–54)	*<0.001*
Vancomycin (167 vs 46) ^b	7 (4, 1–7)	0 (0, 0)	0.158
Treatment after the onset of BSIs
Appropriate antimicrobial treatment	157 (94, 90–98)	43 (93, 86–100)	0.893
Appropriate empirical treatment	62 (37, 30–45)	26 (57, 42–71)	*0.018*

Data are presented as n (%,95% CI) or median (IQR)
Significant variables are appeared in bold and italics text
^aNot all agents listed tested in all isolates
^bThe numbers in parentheses represent the total numbers of E. faecium and E. faecalis isolates performed susceptibility test

ISSN: 2047-2994